These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A seamless phase II/III design with sample-size re-estimation. Bischoff W; Miller F J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428 [TBL] [Abstract][Full Text] [Related]
23. Optimizing the data combination rule for seamless phase II/III clinical trials. Hampson LV; Jennison C Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892 [TBL] [Abstract][Full Text] [Related]
24. A Bayesian predictive two-stage design for phase II clinical trials. Sambucini V Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528 [TBL] [Abstract][Full Text] [Related]
25. Optimal sample sizes for phase II clinical trials and pilot studies. Stallard N Stat Med; 2012 May; 31(11-12):1031-42. PubMed ID: 22052407 [TBL] [Abstract][Full Text] [Related]
26. Continuous toxicity monitoring in phase II trials in oncology. Ivanova A; Qaqish BF; Schell MJ Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702 [TBL] [Abstract][Full Text] [Related]
27. A bayesian approach to the design of phase II clinical trials. Sylvester RJ Biometrics; 1988 Sep; 44(3):823-36. PubMed ID: 3203131 [TBL] [Abstract][Full Text] [Related]
29. Bayesian techniques for sample size determination in clinical trials: a short review. Pezeshk H Stat Methods Med Res; 2003 Dec; 12(6):489-504. PubMed ID: 14653352 [TBL] [Abstract][Full Text] [Related]
30. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach. Cellamare M; Sambucini V Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805 [TBL] [Abstract][Full Text] [Related]
31. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Willan A; Kowgier M Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843 [TBL] [Abstract][Full Text] [Related]
32. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Mayo MS; Gajewski BJ Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034 [TBL] [Abstract][Full Text] [Related]
33. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs. Patel NR; Ankolekar S Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924 [TBL] [Abstract][Full Text] [Related]
34. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials. Sambucini V Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246 [TBL] [Abstract][Full Text] [Related]
35. An optimal three-stage design for phase II clinical trials. Ensign LG; Gehan EA; Kamen DS; Thall PF Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology. Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349 [TBL] [Abstract][Full Text] [Related]
37. Bayesian monitoring of phase II trials in cancer chemoprevention. Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313 [TBL] [Abstract][Full Text] [Related]
38. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Thall PF; Russell KE Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520 [TBL] [Abstract][Full Text] [Related]